Customize View
Named by Company
Named by Competitor
Named by Third Party

Recently disclosed competitors only (within the last two years)
Include Competitors for:Current subsidiaries


Competitors

Recently Disclosed Competitors
Competitor's Name
LTM Revenue ($mm)
LTM Date
Source
Abbott Molecular Inc.
29.26
Sep-30-2001
GenMark Diagnostics, Inc. 2021 Form 10-K
Business Description: Abbott Molecular Inc. engages in molecular diagnostics, and the analysis of DNA, RNA, and proteins at the molecular level for physicians, laboratories, and the patient in the United States and internationally. It manufactures SARS-CoV-2 amplification reagent and control kits. The company offers technologies and assays that detect and monitor infectious diseases, such as HIV, hepatitis, retrovirus, and sexually transmitted diseases; transplantation products; and RealTime PCR systems and assays for various diseases, including HIV, HCV, HCV Genotype II, HBV, CT/NG, and more. It also offers AneuVysion, a multicolor DNA probe kit that provides detection of trisomies (Down syndrome) and sex chromosome aneusomies; FISH, a tool for determining various types of chromosome anomalies; DNA FISH probes for preimplantation, prenatal, and postnatal genetic testing; products for inherited genetic diseases; chromosome enumeration probes; genetic sequencing products; and FISH accessories/FISH general reagents. In addition, it offers systems and assay solutions that detects aberrations in solid tumors; products for hematological cancer. Further, it provides BioView that provides automated cell imaging and analysis solutions for use in cytology, cytogenics, hematology, pathology, and oncology laboratories; m2000 RealTime System for sample preparation, real-time amplification, and detection; mPlus, a laboratory-ready automation solution; ThermoBrite System that provides a system for in-situ hybridization procedures; and VP 2000, which allows the user to enter and save user-defined protocols for various staining procedures and specimen pretreatment procedures. Abbott Molecular Inc. was formerly known as Vysis, Inc. and changed its name to Abbott Molecular Inc. in September 2005. The company was founded in 1989 and is based in Des Plaines, Illinois. As of December 5, 2001, Abbott Molecular Inc. operates as a subsidiary of Abbott Laboratories.
Accelerate Diagnostics, Inc. (NasdaqCM:AXDX)
11.67
Jun-30-2023
GenMark Diagnostics, Inc. 2021 Form 10-K
Business Description: Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.
aprimeo diagnostics GmbH & Co. KG
-
-
GenMark Diagnostics, Inc. 2021 Form 10-K
Business Description: There is no business description for this competitor.
bioMérieux S.A. (ENXTPA:BIM)
3,898.87
Jun-30-2023
GenMark Diagnostics, Inc. 2021 Form 10-K
Business Description: bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Curetis N.V.
1.81
Dec-31-2019
GenMark Diagnostics, Inc. 2021 Form 10-K
Business Description: Curetis N.V., a commercial-stage molecular diagnostics company, provides solutions for laboratories, pharma-companies, and public hospitals in Germany and internationally. The company develops, manufactures, and commercializes molecular microbiology solutions for severe infectious diseases in hospitalized patients with a high unmet medical need that require the detection of a range of pathogens, such as bacteria and fungi, as well as toxins and genetic antimicrobial resistance markers. It provides Unyvero L4 Lysator that is used for sample pre-processing and pathogen lysis; Unyvero A50 Analyzer, which consists of mechanical, electronic, pneumatic, and optical elements; Unyvero C8 Cockpit, a device that acts as the control panel for the L4 Lysator and A50 analyzer; and Unyvero LRT, a panel for various clinically relevant bacterial targets and antibiotic resistance markers. The company also offers Unyvero Application Cartridges, which facilitates the identification of a range of disease relevant microorganisms and antibiotic resistance markers for use in syndromic infectious disease testing; and ARES AMR Database, an Ai-curated database on the genetics of antimicrobial resistances. Its cartridge-based tests are used for pneumonia, implant and tissue, blood stream, intra-abdominal, and urinary tract infections. The company has strategic partnerships with MGI Tech Co. Ltd., Qiagen N.V., Biotest AG, and Sandoz International GMBH. Curetis N.V. was founded in 2007 and is headquartered in Holzgerlingen, Germany.
Danaher Corporation (NYSE:DHR)
30,356.00
Jun-30-2023
GenMark Diagnostics, Inc. 2021 Form 10-K
Business Description: Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians’ offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, municipal, industrial, and natural resource applications. It also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. The company was founded in 1969 and is headquartered in Washington, the District of Columbia.
GenMark Diagnostics, Inc.
171.55
Dec-31-2020
GenMark Diagnostics, Inc. 2021 Form 10-K
Business Description: GenMark Diagnostics, Inc. designs and manufactures multiplex molecular diagnostic solutions to enhance patient care, improve quality metrics, and reduce the total cost-of-care for laboratory professionals, healthcare providers, and customers in the United States and internationally. It offers ePlex systems to streamline the diagnostic workflow from physician order entry to the release of the final report, automate and accelerate order entry and results reporting, notify practitioners that test results are available, enable operation on every shift, minimize system downtime and ensure patients and physicians have access to rapid test results, and reduce avoidable medical errors; ePlex software to support the needs of laboratory and healthcare systems, streamline tasks across the diagnostic process from order-to-report, improve productivity at every level, improve order-to-report turnaround time, reduce labor costs, and eliminate potential transcription errors with bi-directional LIS capabilities; XT-8 systems for processing multiple tests; ePlex panels that include respiratory pathogen and blood culture identification (BCID) Panels to identify the viral and bacterial organisms associated with upper respiratory infection, provide broad coverage of organisms that can lead to sepsis along with the resistance genes, and aid clinicians in the identification of bacterial and fungal organisms; and XT-8 panels to provide sensitive and specific respiratory virus detection with an optimized workflow to maximize laboratory efficiency. The company serves customers through distributors. GenMark Diagnostics, Inc. was formerly known as Osmetech plc and changed its name to GenMark Diagnostics, Inc. in June 2010. The company was incorporated in 2010 and is based in Carlsbad, California. As of April 21, 2021, GenMark Diagnostics, Inc. operates as a subsidiary of Roche Holding AG.
Hologic, Inc. (NasdaqGS:HOLX)
4,038.30
Jul-01-2023
GenMark Diagnostics, Inc. 2021 Form 10-K
Business Description: Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalovirus; Aptima BV and Aptima CV/TV assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. It also offers solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology, and treatment, such as 2D and 3D digital mammography systems, image analytics software, reading workstations, ultrasound imaging, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and ultrasound and connectivity solutions, as well as breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology in the uterus; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; and the CoolSeal portfolio that includes bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Luminex Corporation
437.66
Mar-31-2021
GenMark Diagnostics, Inc. 2021 Form 10-K
Business Description: Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. The company was founded in 1995 and is based in Austin, Texas. It has additional offices in Northbrook, Illinois; Madison, Wisconsin; Seattle, Washington; ‘s-Hertogenbosch, the Netherlands; Shanghai, China; Kowloon, Hong Kong; Tokyo, Japan; and Toronto, Canada. As of July 14, 2021, Luminex Corporation operates as a subsidiary of DiaSorin S.p.A.
Mobidiag Oy
27.84
-
GenMark Diagnostics, Inc. 2021 Form 10-K
Business Description: Mobidiag Oy, doing business as Mobidiag Ltd., develops and provides molecular diagnostics for infectious diseases and antibiotic resistances in Finland and internationally. The company offers PCR-based tests for acute care conditions, such as gastrointestinal and respiratory infections, antimicrobial resistance management, healthcare associated infections, and Sepsis. Its products include Novodiag, an automated platform that enables immediate detection of infectious diseases directly from a single use cartridge; and Amplidiag, a family of diagnostic tests for mid to high-volume screening of infectious diseases. The company was founded in 2000 and is headquartered in Espoo, Finland with additional offices in France, United Kingdom, and Sweden. As of June 17, 2021, Mobidiag Oy operates as a subsidiary of Hologic, Inc.
Qiagen N.V. (NYSE:QGEN)
1,979.37
Jun-30-2023
GenMark Diagnostics, Inc. 2021 Form 10-K
Business Description: QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Randox Laboratories Ltd.
388.13
-
GenMark Diagnostics, Inc. 2021 Form 10-K
Business Description: Randox Laboratories Ltd. researches, designs, develops, manufactures, markets, and exports healthcare diagnostic products. The company offers biochip analyzers, immunoassays, and molecular diagnostics; clinical chemistry analyzers; diagnostic reagents; and multi-analyte liquid tumor marker controls. It also provides RIQAS, an external quality assessment scheme; and contract manufacturing services. In addition, the company offers Randox Molecular that provides a range of molecular arrays and assay formats to offer diagnostic, prognostic, and predictive solutions for infectious diseases, cardiovascular diseases, and cancer. It serves hospital laboratories, forensic laboratories, A&E units, food and wine laboratories, sports organizations, horse racing authorities, veterinary clinics, pharmaceutical companies, and CRO companies in the United Kingdom and internationally. The company sells products online. Randox Laboratories Ltd. was founded in 1982 and is based in Crumlin, United Kingdom.
Robert Bosch GmbH
92,911.62
Dec-31-2022
GenMark Diagnostics, Inc. 2021 Form 10-K
Business Description: Robert Bosch GmbH, together with its subsidiaries, provides technology and services in Europe, the Americas, and the Asia Pacific. It operates through Mobility Solutions, Industrial Technology, Consumer Goods, and Energy and Building Technology segments. The Mobility Solutions segment provides gasoline systems, diesel systems, chassis systems control products, electrical drives, starter motors and generators, car multimedia products, automotive electronics, and automotive aftermarket and steering products. The Industrial Technology segment offers drive, control, and actuator solutions for the factory automation, plant construction and engineering, mobile machinery, and commercial vehicles. This segment also provides process and packaging solutions for the pharmaceuticals, foodstuffs, and confectionery industries, as well as for the beverages industry. The Consumer Goods segment produces and distributes power tools, such as tools for the trade, industry, and DIY; and accessories and garden tools, as well as industrial tools and measuring equipment. It also offers household appliances for cooking, washing-up, washing, drying, cooling, freezing, floor care, etc. The Energy and Building Technology segment manufactures heaters, heat pumps, solar thermal systems, solid-fuel boilers, cogeneration plants, and industrial boilers. It also provides security systems comprising video-surveillance, intrusion-detection, fire-detection, and voice alarm systems; and access-control, and building management systems, as well as professional audio and conference systems. The company has a strategic partnership with Software AG for the Internet of Things Cloud. The company was formerly known as Workshop for Precision Mechanics and Electrical Engineering and changed its name to Robert Bosch GmbH in 1937. The company was founded in 1886 and is based in Gerlingen, Germany.
Roche Diagnostics GmbH
1,380.27
Dec-31-1996
GenMark Diagnostics, Inc. 2021 Form 10-K
Business Description: Roche Diagnostics GmbH manufactures instruments and reagents for genome sequencing, microarray analysis, nucleic acid purification, real-time PCR, and cell analysis. It offers sequencing, PCR/RT-PCR, sample preparation, cell biology, and discovery reagent solutions for cancer research, cellular analysis, gene expression, gene knockdown, protein expression, and bio-processing/manufacturing applications. The company also provides resources to support the life science community, including online technical and application information, on-site product supply programs, technical and customer service; and specialty bio-chemicals for industrial applications and custom manufacturing. It offers its products online. Roche Diagnostics GmbH was formerly known as Boehringer Mannheim GmbH and changed its name to Roche Diagnostics GmbH in January 1999. The company was founded in 1859 and is based in Mannheim, Germany. Roche Diagnostics GmbH operates as a subsidiary of Roche Holding AG.
Seegene, Inc. (KOSDAQ:A096530)
331.44
Jun-30-2023
GenMark Diagnostics, Inc. 2021 Form 10-K
Business Description: Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of six SNPs in factor II, factor V, and MTHFR genes; BRAF mutation characteristic for papillary thyroid carcinoma from samples of thyroid tissue, fine needle aspiration biopsy, H&E slides, and paraffin-embedded tissues; Apolipoprotein E genotypes; and BCR/ABL fusion gene from blood and whole bone marrow. In addition, it offers PCR machines; vial cap management systems; nucleic acid extraction systems; automated liquid handling workstations from nucleic acid extraction to PCR setup; and real-time PCR detection systems. The company has a collaboration with Werfen for the joint development of syndromic qPCR assays. Seegene, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
Siemens Aktiengesellschaft (XTRA:SIE)
81,057.62
Jun-30-2023
GenMark Diagnostics, Inc. 2021 Form 10-K
Business Description: Siemens Aktiengesellschaft, a technology company, focuses in the areas of automation and digitalization in Europe, Commonwealth of Independent States, Africa, the Middle East, the Americas, Asia, and Australia. It operates through Digital Industries, Smart Infrastructure, Mobility, Siemens Healthineers, and Siemens Financial Services segments. The Digital Industries segment offers automation systems and software for factories, numerical control systems, motors, drives and inverters, and integrated automation systems for machine tools and production machines; process control systems, machine-to-machine communication products, sensors and radio frequency identification systems; software for production and product lifecycle management, and simulation and testing of mechatronic systems; and cloud-based industrial Internet of Things operating systems. The Smart Infrastructure segment offers products, systems, solutions, services, and software to support sustainable transition in energy generation from fossil and renewable sources; sustainable buildings and communities; and buildings, electrification, and electrical products. The Mobility segment provides passenger and freight transportation, such as vehicles, trams and light rail, and commuter trains, as well as trains and passenger coaches; locomotives for freight or passenger transport and solutions for automated transportation; products and solutions for rail automation; electrification products; and intermodal solutions. The Siemens Healthineers segment develops, manufactures, and sells various diagnostic and therapeutic products and services; and provides clinical consulting services. The Siemens Financial Services segment offers debt and equity investments; leasing, lending, and working capital financing solutions; and equipment, project, and structured financing solutions. Siemens Aktiengesellschaft was founded in 1847 and is headquartered in Munich, Germany.
T2 Biosystems, Inc. (NasdaqCM:TTOO)
13.20
Jun-30-2023
GenMark Diagnostics, Inc. 2021 Form 10-K
Business Description: T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
*denotes proprietary relationship